Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning trading, 101 companies set new 52-week highs.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 167 companies set new 52-week highs.
Earnings Outlook For Repligen
Repligen (NASDAQ:RGEN) announces its next round of earnings this Tuesday, July 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.
Repligen To Buy Polymem For An Undisclosed Sum
Repligen Corporation (NASDAQ:RGEN) has agreed to acquire France-based Polymem S.A., a provider of hollow fiber membranes and modules. “The acquisition significantly expands…
Repligen Corporation Announces Agreement To Acquire Polymem S.A.; Size Of Deal Not Disclosed
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A.
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell
• Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.